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ABSTRACT 1 
Purpose: To examine the influence of corneal allograft rejection on the survival of 2 
penetrating corneal transplantation, to review the status of conventional therapies to 3 
improve graft survival, and to consider prospects for alternative approaches to reduce 4 
the impact of rejection. 5 
Design: Perspective, including prospective, observational cohort study. 6 
Methods: An examination of the literature on human corneal graft rejection and data 7 
from the Australian Corneal Graft Registry, reviewed in the context of clinical 8 
experience. 9 
Results: Corneal graft outcome is not improving with era. The sequelae of inflammation, 10 
whether occurring before corneal transplantation or subsequently, exert a profound 11 
influence by predisposing the graft to rejection. Of the developments that have been 12 
instrumental in reducing rejection in vascularized organ transplantation, living–related 13 
donation is not an option for corneal transplantation. However, HLA matching may be 14 
beneficial and requires reassessment. The evidence-base to support the use of 15 
systemic immunosuppressive agents in corneal transplantation is thin, and topical 16 
glucocorticosteroids remain the drugs of choice to prevent or reverse rejection episodes. 17 
Experimental approaches to local allospecific immunosuppression, including the use of 18 
antibody-based reagents and gene therapy, are being developed but may be difficult to 19 
translate from the laboratory bench to the clinic. 20 
Conclusions: Corneal allograft rejection remains a major cause of graft failure. High-21 
level evidence to vindicate the use of a particular approach or treatment to prevent or 22 
treat corneal graft rejection is lacking. In the absence of extensive data from 23 
randomized, controlled clinical trials, corneal graft registers and extrapolation from 24 
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experimental models provide some clinically useful information. 1 
2 
  
4 
Corneal transplantation, practiced for a century, falls well short of its full therapeutic 1 
potential. The success rate of corneal transplantation is less than is generally 2 
appreciated. Allograft rejection is the most common cause of corneal graft. In this 3 
centenary year of penetrating corneal transplantation1 and at a time of unprecedented 4 
success in other areas of clinical transplantation, it is timely to consider the current 5 
status of the procedure, the way in which outcomes are affected by allograft rejection, 6 
and the strategies that can be used to manage rejection. To this end, we have 7 
summarized pertinent results from the Australian Corneal Graft Registry, a large 8 
repository of corneal transplantation data, reviewed the status of conventional therapies 9 
to improve graft survival, and considered the prospects for alternative approaches to 10 
reduce the impact of rejection. 11 
 12 
THE VALUE OF TRANSPLANT REGISTRIES 13 
Patient registries allow the collection of comprehensive information about transplantation 14 
that is difficult to obtain in any other way. Randomized, controlled clinical trials provide 15 
the highest level of evidence, but relatively few such trials relating to corneal 16 
transplantation have ever been reported. Clinical trials are difficult to perform in the 17 
surgical context, and patient registries provide a useful, alternative source of data. They 18 
can provide information on the long-term follow-up on large numbers of subjects, 19 
enabling robust multivariate analysis to be performed. 20 
The Australian Corneal Graft Registry (ACGR) was established in 1985 to 21 
measure the long-term survival of corneal grafts and to identify the factors which 22 
influence graft survival.2 It is administered from the Department of Ophthalmology at the 23 
Flinders Medical Centre in Adelaide, Australia. Individual surgeons handled the informed 24 
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consent process for each patient according to local legislative requirements, to permit 1 
information to be lodged with the register. The Institutional Ethics Committee of Flinders 2 
University oversees the operations of the register, which are carried out in accordance 3 
with the Declaration of Helsinki. Initially it operated independently. Now it has 4 
collaborative partners through the recently-formed Eye Banks of Australia and New 5 
Zealand Association. The member banks of this organization contribute to the 6 
acquisition of data from surgeons using corneas distributed from the various banks. The 7 
surgeons receive a registration form with each donor cornea and return the form to the 8 
ACGR. They are also sent annual follow-up forms by the ACGR. The process is not 9 
compulsory, but more than 90% of the corneal grafts performed in Australia each year 10 
are registered. Recent analyses included data from 15,000 corneal grafts, some of 11 
which had been followed for almost 20 years. De-identified data, analyses and a 12 
commentary are published every two years in the form of a report, distributed to 13 
contributors and other interested parties around the world.  14 
Registries have limitations – and detractors. The primary data collection is left in 15 
the hands of a large number of contributors – over 500 in the case of the ACGR. In 16 
consequence, there are difficulties in ensuring uniformity of observation. In addition, 17 
there are inevitable losses to follow-up. Registries are not population-based surveys. 18 
Only the data entered can be analyzed, and no epidemiological conclusions can be 19 
drawn. For these reasons, there is division in the evidence-based medicine movement 20 
about the place of registries. The purists, principally those conducting clinical trials, 21 
reject attempts to consider registry data as high-level evidence. However without 22 
registries, there would be little evidence upon which to base clinical transplantation 23 
practice. Registries provide information invaluable to those managing clinical problems. 24 
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A more detailed analysis of the benefits and limitations of transplant patient registries 1 
has been reviewed elsewhere.3 2 
 3 
MEASURING THE OUTCOMES OF CORNEAL TRANSPLANTATION 4 
Graft failure is one important measure of the outcome of corneal transplantation. 5 
Although not all patients with functioning grafts - or even good levels of post-operative 6 
best-corrected visual acuity - are happy with their situation, a non-functioning graft is 7 
strongly associated with patient dissatisfaction. Furthermore, graft failure is easily 8 
recognized. A corneal graft is either functioning or it is not. Graft failure is thus a crisp 9 
end-point for clinical studies. The standard description used in the ACGR is loss of 10 
corneal transparency and persistent, increased corneal thickness. 11 
Since the most common reason to undertake corneal transplantation is to 12 
improve vision, visual function also needs to be considered as an outcome measure.4 13 
However measurements of visual function do not provide clear endpoints. There are a 14 
number of reasons for this. Visual acuity measurement is only a surrogate measure for 15 
visual disability. Some patients with poor acuity function well and others with excellent 16 
acuity function poorly, findings that tend to influence clinical management. Patients who 17 
function adequately are not driven to pursue the best possible visual correction, nor to 18 
wear it, if inconvenient. Furthermore, the ability of practitioners to provide the best 19 
refractive correction is variable. 20 
The outcome of penetrating corneal transplantation is poorer than is generally 21 
appreciated. Long-term survival is about 60% at ten years. Survival is similar for both 22 
penetrating and lamellar grafts but the outcome for limbal grafts performed for limbal 23 
stem cell dysfunction is considerably worse, with a five-year survival of around 35% 24 
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(Figure 1). 1 
 2 
CLINICAL MARKERS OF CORNEAL GRAFT OUTCOME 3 
A number of clinical factors are well established to influence the outcome of corneal 4 
transplantation. The most obvious of these is the condition that resulted in the need for 5 
transplantation in the first place. Patients with keratoconus have favorable outcomes 6 
compared with those receiving grafts for acquired disorders such as herpetic eye 7 
disease or trauma (Figure 2). 8 
Inflammation is an independent variable associated with corneal graft failure. A 9 
corneal graft put into a recipient bed that has never been inflamed has a much greater 10 
chance of survival than one placed in a recipient bed that has been inflamed at some 11 
stage in the past. Grafts that are put in a recipient bed inflamed at the time of the 12 
surgery do worst of all (Figure 3). In the post-operative period, the occurrence of an 13 
inflammatory event such as a suture abscess or recurrent herpes simplex virus infection 14 
also increases the risk of graft failure. 15 
 Neovascularization is an almost invariable consequence of acute or chronic 16 
corneal inflammation. The extent of vascularization of the recipient cornea at the time of 17 
corneal transplantation correlates strongly with graft survival. The more extensive the 18 
vascularization, the greater the risk of graft failure (Figure 4). Similarly, vascularization of 19 
the graft in the post-operative period is also associated with an increased risk of graft 20 
failure. 21 
Elevated intraocular pressure can also be thought of as a marker of the extent of 22 
inflammation. Extensive inflammation can involve the drainage apparatus, reducing the 23 
functional reserve capacity of aqueous outflow and resulting in raised intraocular 24 
  
8 
pressure. A raised intraocular pressure at the time of corneal transplantation is 1 
associated with an increased risk of graft failure. So too is a history of raised intraocular 2 
pressure at some time in the past, even if it has reduced to normal by the time of 3 
surgery (Figure 5). Similarly, an episode of raised intraocular pressure in the post-4 
operative period is associated with an increased risk of graft failure. 5 
Other clinical features associated with an increased risk of graft failure may reflect 6 
allosensitization. First grafts fare better than subsequent grafts in the same eye. The 7 
more grafts a person has had, the lower the probability of success (Figure 6). Similarly, 8 
an episode of rejection in the post-operative period increases the chance of subsequent 9 
episodes and ultimate graft failure. 10 
 11 
THE MAINTENANCE AND EROSION OF IMMUNE PRIVILEGE 12 
The early success of corneal transplantation was ascribed to the immune privilege of the 13 
anterior segment of the eye.5 The notion is correct – up to a point. Immune privilege is 14 
maintained in the normal cornea by a number of mechanisms,6 but is readily eroded by 15 
the sequelae of inflammation. 16 
Accessory cells, including dendritic cells and macrophages, are necessary for an 17 
effective immune response to a foreign antigen. The normal human cornea is relatively 18 
acellular. However, accessory cells are not completely absent. Langerhans cells are 19 
present in the peripheral epithelium, and a few interstitial dendritic cells can be found in 20 
the central and peripheral stroma.7,8 Major histocompatibility complex (MHC) antigen 21 
expression – HLA in man - is limited in the normal cornea. MHC class I determinants are 22 
expressed on epithelium, stromal keratocytes and probably on endothelium.9 Class II 23 
determinants are largely restricted to accessory cells.7-10 ABO blood-group antigens are 24 
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expressed on the epithelium and endothelium.11 The normal cornea, along with the 1 
testis and brain, expresses Fas ligand – a mechanism for inducing apoptosis in 2 
lymphocytes finding their way into the cornea.12 Blood vessels and lymphatics are 3 
absent from the normal cornea, which depends upon nutrients from the tear film and 4 
aqueous humor. Furthermore the vasculature of the anterior chamber has tight 5 
capillaries which sequestrate the aqueous humor from the systemic circulation, thereby 6 
forming the blood-aqueous barrier.13 The aqueous humor also contributes to privilege by 7 
way of its immunosuppressive cytokine and peptide profile.6 It contains relatively high 8 
levels of transforming growth factor-2, calcitonin gene-related peptide, vasoactive 9 
intestinal peptide and -melanocyte-stimulating hormone. 10 
All of these mechanisms contribute to the immune privilege of the anterior 11 
chamber and cornea – and all are eroded by inflammation. Inflammation increases the 12 
number of accessory cells in the cornea.10 Even when the clinical evidence of 13 
inflammation has disappeared, many years after an inflammatory event, an increased 14 
number of accessory cells are present in the cornea. Corneal graft survival in humans 15 
correlates with the number of these cells found in the recipient bed at the time of corneal 16 
transplantation.14 Inflammation also increases MHC class I and class II antigen 17 
expression.15 Inflammatory cells produce large amounts of vascular endothelial cell 18 
growth factors, resulting in corneal neovascularization and lymphangiogenesis.16 19 
Inflammation also affects microvascular competence in the anterior chamber, resulting 20 
in erosion of the blood-aqueous barrier and exposing the anterior chamber, including the 21 
cornea, to systemic influences.17,18 The access of pro-inflammatory molecules including 22 
cytokines to the aqueous humor contributes to the erosion of privilege. 23 
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The influence of inflammation on the cornea, whether before transplantation or 1 
subsequently, is thus profound. Inflammatory pathological process decrease the chance 2 
of achieving engraftment. In contrast, a normal cornea can be grafted into a normal 3 
cornea with little risk of rejection. The closest clinicians come to this is performing 4 
corneal grafts on patients with uncomplicated keratoconus. However, once a cornea has 5 
been inflamed, it is never the same again. 6 
 7 
THE IMPACT OF ALLOGRAFT REJECTION ON CORNEAL GRAFT SURVIVAL 8 
Corneal endothelial cell function is plainly critical to corneal graft function – endothelial 9 
cell failure results in corneal edema. A number of pathological processes may contribute 10 
to graft failure, of which allograft rejection is the most obvious. It is an acute process, 11 
manifesting clinically with ocular inflammation, keratic precipitates on the endothelium 12 
that are often assembled in a line, and corneal edema. 13 
 Rejection is sometimes reversible but often it is not. Even if a rejection episode 14 
can be reversed, it carries a poor prognosis for the occurrence of subsequent episodes 15 
and ultimate graft failure. Acute corneal allograft rejection is responsible for about one-16 
third of corneal graft failures reported to the ACGR,2 but the true figure may be higher 17 
because rejection may go unrecognized. Inflammation around a stitch, infection 18 
complicating an epithelial defect, uveitis, or even ocular wall inflammation such as 19 
conjunctivitis may precipitate an allograft response. Patients with herpetic infection 20 
affecting the corneal graft may be similarly affected. Whatever the cause, the underlying 21 
condition may obscure the classical signs of corneal rejection. 22 
 The corneal endothelium of a graft may fail for no apparent reason. There can be 23 
a gradual, although sometimes fluctuating, development of corneal edema – so-called 24 
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late endothelial cell failure - the causative factor of which is uncertain.18  1 
 2 
CELLULAR AND MOLECULAR MECHANISMS IN CORNEAL ALLOGRAFT REJECTION 3 
A line of best fit through the accumulated data from many laboratory experiments 4 
performed around the world over many years suggests the following sequence of events 5 
during corneal allograft rejection (Figure 7).19 6 
 7 
Accumulation of accessory cells 8 
The tendency to allograft rejection is related to the number of accessory cells in the 9 
recipient cornea at the time of corneal transplantation – the higher the count of cells in 10 
the recipient button, the greater the chance of subsequent graft failure.14 Accessory cells 11 
can move into the graft from the surrounding host cornea and are recruited from the 12 
circulation into the cornea during inflammation and wound healing. Histocompatibility 13 
antigens shed from a transplant may be internalized by host accessory cells and 14 
presented to naïve host T cells.20 This is referred to as indirect antigen presentation. In 15 
an alternative pathway to sensitization, donor accessory cells that have been carried as 16 
passenger cells in the donor organ can trigger host T cells directly.20 This is referred to 17 
as direct antigen presentation. There is evidence that both pathways operate after 18 
corneal transplantation.21 The therapeutic implication is there is little point in trying to 19 
deplete antigen-presenting accessory cells from the graft to increase graft survival, 20 
because such interventions will influence the direct pathway only. 21 
 22 
Processing and presentation of donor antigen 23 
Antigen presentation has been the focus of intense attention from transplant biologists 24 
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and much is known of the process at a molecular level. The interaction between the 1 
antigen-presenting cell and the host immunocyte (the naïve T cell) occurs within the 2 
draining lymph node and is modulated by co-stimulatory interactions between molecules 3 
on the surface of the accessory cell and the lymphocyte.22 The effect of these co-4 
stimulatory interactions may be enhancing or suppressing. 5 
The cornea supposedly lacks formal lymphatic drainage and thus the location at 6 
which presentation of cornea-derived alloantigen occurs is open to conjecture. This is of 7 
significance for those developing immunosuppressive therapies for corneal 8 
transplantation. Antigen presentation is the most vulnerable point of the allograft 9 
response, offering the prospect of allospecific suppression, but to which anatomical site 10 
should new drugs be targeted? Antigen presentation could occur in the cornea, as the 11 
essential elements of the process are there, but mounting experimental evidence 12 
suggests that it occurs elsewhere. It might occur in the uvea,23 the conjunctiva-13 
associated lymphoid tissue,24 the draining lymph nodes,25 or beyond. Antigen may leave 14 
the eye as soluble antigen26 or be carried by mobile accessory cells.27 15 
 16 
T cell activation, proliferation, and clonal expansion 17 
Antigen presentation activates naïve T cells, resulting in T cell proliferation and clonal 18 
expansion. Clonal expansion is promoted by the influence of interleukin 2 (IL-2). The 19 
most potent action of the calcineurin blockers such as cyclosporine and FK 506 is on IL-20 
2-controlled clonal T cell expansion.28 These two agents have been ineffective in 21 
prolonging corneal graft survival when delivered topically, suggesting that clonal 22 
expansion does not occur in the cornea. 23 
 24 
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The effector arm – graft destruction 1 
The efferent arm of the allograft response can destroy all cells of the donor cornea, but it 2 
is the corneal endothelium, with its limited replicative capacity, that is the major target of 3 
the corneal allograft response. Damage to the graft is primarily cell-mediated; antibody 4 
does not seem to play a significant role in corneal graft rejection. The CD4+ T 5 
lymphocyte plays a central role in recruiting effector cells into the graft. Damage appears 6 
to be wrought by a wide range of cells, including macrophages, polymorphonuclear 7 
granulocytes and NK cells, via a range of cytokines including tumor necrosis factor- 8 
and interferon-. CD8+ T lymphocytes are also present in rejecting corneal grafts and 9 
have the capacity to cause cell damage, but corneal graft rejection still occurs in animals 10 
deficient in CD8+ cells.29 11 
 12 
CURRENT CLINICAL INTERVENTIONS TO ABROGATE CORNEAL ALLOGRAFT REJECTION 13 
Topical glucocorticosteroids can prevent and reverse corneal allograft rejection. They 14 
achieve this through multiple mechanisms,28 one of the most important of which is 15 
probably to inhibit leukocyte migration into the cornea, thereby abrogating the efferent 16 
arm of the allograft response. It is unlikely that a more specific intervention would be as 17 
effective. There is too much redundancy for interference with any single element of the 18 
efferent arm of the response to be useful: block one molecule or cell type and another 19 
will take over. Corticosteroids are therefore likely to remain the most effective of the 20 
conventional treatments for established corneal graft rejection. 21 
 22 
CAN INTERVENTIONS USED IN ORGAN TRANSPLANTATION BE APPLIED TO THE CORNEA? 23 
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The results of transplantation in other areas of medicine have improved remarkably over 1 
the last 40 years. Renal transplantation is a valid example: since the procedure was first 2 
carried out in the 1960s, there have been steady improvements in outcome.30 This is in 3 
contrast to corneal transplantation, where it has not been possible to demonstrate any 4 
improvement in outcome over a similar period. Analysis by era for the last 20 years 5 
within the ACGR database shows no tendency for corneal graft survival to increase.31 6 
Perhaps this is not surprising, as very little new has been introduced into the clinical 7 
practice of corneal transplantation since the adoption of microsurgical techniques and 8 
materials decades ago, and the use of topical corticosteroids. 9 
Three major developments have contributed to the 50% improvement in renal 10 
graft outcomes in recent years: better histocompatibility matching, improved systemic 11 
immunosuppression, and the use of living-related donors. Neither matching nor the use 12 
of systemic immunosuppression is widely practiced in corneal transplantation. The use 13 
of living-related donors is clearly not justifiable, but both tissue matching and systemic 14 
immunosuppression deserve further examination. 15 
 16 
Histocompatibility antigen matching in corneal transplantation 17 
Histocompatibility matching for MHC determinants has not found favor amongst 18 
clinicians in many parts of the world. This is doubtless in part because the American 19 
Collaborative Corneal Transplant Study (CCTS) reported no benefit from HLA class I 20 
and class II antigen matching in corneal transplantation, although it did support, 21 
surprisingly, a modest benefit from ABO antigen matching.32 In northern Europe a 22 
different attitude prevails. A benefit from MHC matching has been reported from 23 
Canada,33 Holland34 and Germany,35 as well as from the United Kingdom.36 In patients 24 
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considered to be of high risk of rejection, the improvement obtained with matching was 1 
of the order of forty percent, compared with those who were less well-matched.35 2 
Why is there such a disparity between the results reported from the USA, Canada 3 
and Europe? Perhaps the results of the CCTS have been too readily accepted. In a 4 
paper published after the clinical results were first reported, a high error rate in the 5 
typing of patients included in the CCTS study was discovered.37 This error rate was 6 
about 12% at the HLA A locus, 20% at the B locus, and 45% at the DR locus. Völker-7 
Dieben and colleagues have since used a mathematical model to demonstrate that an 8 
error rate in DR locus typing of more than 10% is enough to obscure any chance of 9 
detecting a benefit from matching.38 10 
Perhaps it is time to re-examine the use of HLA matching for corneal 11 
transplantation: the results from Europe cannot be ignored, and molecular techniques 12 
have facilitated ever-more accurate typing. Matching may be the only currently-available 13 
intervention that can improve outcome for high-risk patients without exposing them to 14 
any significant risks. Efforts to find a match may delay surgery, but the possibility of 15 
unacceptably long delays can be assessed prior to surgery by considering the frequency 16 
of a given recipient’s HLA antigens within the population from which donor corneas are 17 
drawn.39 How practical it would be to introduce extensive matching programs is another 18 
issue. Histocompatibility matching for corneal transplantation within Europe is performed 19 
in the context of a major international network. Provision of essential infrastructure 20 
funding and large, reasonably homogeneous populations separated by relatively small 21 
distances have contributed to the success of these programs. Whether similar programs 22 
are possible in larger, more fragmented and less densely populated countries – such as 23 
the USA or Australia – is an unresolved issue. 24 
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 1 
The use of systemic immunosuppression in corneal transplantation 2 
Systemic immunosuppression is not widely applied in corneal transplantation, even for 3 
patients at high risk of rejection. There are two reasons for this. The evidence-base for a 4 
beneficial effect is limited, and the clinical context of corneal transplantation is different 5 
from that of other forms of transplantation in which systemic immunosuppression is 6 
readily justified and widely used. 7 
The evidence-base supporting the use of systemic immunosuppression in corneal 8 
transplantation is limited, being mostly confined to cyclosporine, and the results are 9 
inconsistent.40-44 Some investigators have demonstrated a beneficial effect40,41  and 10 
others42-44 have failed to find any improvement in outcome. The efficacy of systemic 11 
mycophenolate mofetil in corneal transplantation has yet to be established. 12 
A benefit of systemic immunosuppression in corneal transplantation might well 13 
have been expected, given that the corneal allograft reaction is not too dissimilar to 14 
organ graft rejection, where the advantages have been obvious. However, the allograft 15 
response is more easily suppressed in some tissues than in others. For example, it is 16 
more difficult to prolong skin allografts than renal allografts with immunosuppression. It 17 
would seem that the cornea is towards the more difficult end of the spectrum with 18 
respect to immunosuppression. 19 
There are problems in planning and conducting randomized, controlled clinical 20 
trials of systemic immunosuppression for corneal transplantation, because of the serious 21 
risks entailed.45 For the most part, corneal transplantation is carried out on patients who 22 
are otherwise well. They may be disabled and frustrated by poor vision, but their general 23 
health is not threatened. This contrasts with those requiring a transplant of a solid organ 24 
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such as a kidney, heart, lung, or liver. Such people need an allograft to survive, or in the 1 
case of renal recipients, to escape dialysis. For this group of patients, the risk of a 2 
complication from systemic immunosuppression is the lesser of two evils. 3 
Some patients with poor vision who would benefit from a corneal transplant are 4 
so affected by their predicament, that they are prepared to accept the risks of systemic 5 
immunosuppression. This is a small minority of patients. However, for those who are in 6 
need of immunosuppression and understand the risks involved, there is no evidence 7 
that any one regimen of immunosuppression is any better than any other. In the 8 
absence of data, it is reasonable to extrapolate from protocols used in other organ 9 
transplantation. At present this involves the use of a calcineurin inhibitor such as 10 
cyclosporine or FK506, and an anti-proliferative agent such as azathioprine or 11 
mycophenolate. It is usually preferred that this aspect of the patient’s management be 12 
carried out in collaboration with a physician experienced in immunosuppression for other 13 
clinical indications – such as an internist involved in solid organ transplantation. 14 
Probably as much immunosuppression is needed to prevent corneal graft rejection as is 15 
required to prevent the rejection of any solid organ. Any temptation to use less than this 16 
may not reduce the risk of rejection, but may still expose patients to the side effects of 17 
immunosuppressive agents. 18 
 19 
ALTERNATIVE APPROACHES: THE PURSUIT OF REGIONAL IMMUNOLOGICAL BLOCKADE 20 
Given that few of the therapeutic interventions that have been applied to other areas of 21 
clinical transplantation are applicable to corneal transplantation, it will be necessary to 22 
develop alternative strategies that are especially suited to the eye. These must take into 23 
account the unique features of the eye, the elements of the corneal allograft response 24 
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that are different and can be exploited, and the clinical reality of corneal transplantation. 1 
For example, the eye is readily accessible compared with most other transplantable 2 
organs and tissues. It is therefore possible to deliver medication topically in the form of 3 
eye drops. In addition, the donor cornea used for transplantation can be manipulated ex 4 
vivo over a relatively long period while in storage medium prior to surgery. 5 
 New approaches currently being explored in experimental animals are based on 6 
developments in molecular medicine – the exploitation of an understanding of the 7 
production of proteins by cells and how these proteins function. Two broad approaches 8 
are applicable: first, the production of peptides or small proteins that can be delivered to 9 
the eye topically and second, the in vivo production of proteins by a gene therapy 10 
approach. The anterior segment of the eye is amenable to both approaches. 11 
 12 
Topically delivered antibodies to prolong graft survival 13 
Systemic immunosuppressive intervention with polyclonal and monoclonal antibodies 14 
directed at key elements of the allograft response is well established in transplantation 15 
medicine. Antibodies are currently used to “rescue” vascularized organ grafts 16 
undergoing rejection. There are anecdotal reports of this general approach being 17 
applied to corneal transplantation, with good results.46 However, the systemic 18 
administration of potent immunosuppressive antibody is not without risk. The use of 19 
antibody reagents to generate an allospecific regional blockade would be ideal. 20 
Whole antibody molecules, with a molecular weight of around 150 kDa, cannot 21 
pass into the anterior chamber after topical administration to the ocular surface. In order 22 
to overcome this problem, we have explored the possibility of using antibody fragments 23 
for topical delivery to the eye.47 Using molecular techniques, antibody fragments 24 
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comprising just the variable region domains of the heavy and light chains of an 1 
immunoglobulin molecule can be constructed. Such fragments can be considered as 2 
free antigen-binding domains. For use in experimental systems, we constructed a 3 
murine antibody fragment with a molecular weight of 28kD. The fragment had the same 4 
specificity for antigen as the parental antibody from which it was engineered. 5 
Experiments with corneas mounted in isolated corneal perfusion chambers in vitro 6 
showed that this and similar model antibody fragments could cross the cornea into the 7 
anterior chamber after topical delivery to the ocular surface.47 The fragment was also 8 
shown to be able to penetrate through the corneas of rabbits in vivo. Whether such 9 
antibody constructs will prove to be useful immunosuppressants for corneal 10 
transplantation remains to be determined. 11 
 12 
Gene therapy in corneal transplantation 13 
The cornea is well-suited to gene therapy. The tissue is accessible and corneal 14 
endothelial cells are readily transfected. Transfection can be achieved ex vivo, in the 15 
case of a donor cornea, or in vivo by injecting the construct into the anterior chamber. 16 
Either way, high transfection rates can be achieved with appropriate vector systems, 17 
especially with replication-deficient viral vectors. High rates of production of transgenic 18 
protein by corneal endothelium can be achieved and gene expression can be 19 
surprisingly persistent, perhaps because the endothelium (at least in humans) does not 20 
divide. The relative immune privilege of the cornea and anterior chamber may permit the 21 
use of vectors which are otherwise immunogenic. 22 
A number of investigators have reported prolongation of corneal allograft survival 23 
following ex vivo gene transfer to the donor cornea in the mouse, rat, rabbit and sheep.48 24 
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We have found corneal transplantation in the sheep to be a satisfactory model for a 1 
number of reasons. The animals are large, robust and outbred – important attributes for 2 
preclinical studies on gene therapy. Corneal graft rejection is swift, at around three 3 
weeks in untreated animals, and there is no tendency for rejection to be transient or 4 
reversible, because the endothelium is non-replicative. In small rodents such as rats and 5 
mice, the rejection process may be quite short and healing of the endothelium may 6 
occur, so that corneal clarity is restored. A number of ovine-specific reagents are 7 
available. When donor ovine corneas were transfected ex vivo with cDNA for ovine 8 
interleukin 10 (IL-10) using an adenoviral vector, an impressive and significant 9 
prolongation of subsequent corneal allograft survival was observed.49 IL-10 is an 10 
immunomodulatory cytokine with multiple points of action. It affects accessory cell 11 
function at an early step in the allograft response. That IL-10 is effective in prolonging 12 
graft survival when the endothelium of the grafted cornea is transfected suggests that 13 
accessory cells within the cornea and immediate ocular environs are being modulated. 14 
A number of potential problems need to be overcome before gene therapy can be 15 
used to prolong human corneal allograft survival. Most investigators in the field have 16 
thus far used adenoviral vectors, which may not be optimal. Objections have been 17 
raised to these vectors on the basis of potential toxicity, citing the death of a patient in 18 
the United States after systemic gene therapy. There are also questions surrounding the 19 
period of gene expression which can be expected with adenoviral vectors. Adenoviral 20 
vectors remain episomal. Lentiviral and adeno-associated viral vectors integrate into 21 
genomic DNA and thus can be expected to provide more prolonged transgene 22 
expression. 23 
 24 
  
21 
BARRIERS BETWEEN THE LABORATORY AND CLINICAL PRACTICE 1 
Even if the use of antibody fragments or gene therapy can be shown to be effective in 2 
prolonging corneal graft survival in animal models, there remains a long and difficult 3 
path to clinical practice. Regulatory requirements are likely to be arduous. High levels of 4 
public suspicion concerning genetic manipulation ensure this. Complying with regulatory 5 
requirements is likely to be costly and beyond the resources of academic institutions. 6 
Commercial partners will be required and they may be difficult to find. The 7 
pharmaceutical industry will look at the high levels of investment needed, and expect 8 
high returns to cover the investment. The returns from a relatively small clinical domain 9 
such as corneal transplantation may not justify such investment. Ophthalmologists and 10 
the research programs they support must take the lead, and ensure the developments 11 
required for corneal transplantation to fulfill its potential are achieved. Extrapolations 12 
from other branches of experimental transplantation are unlikely to be useful: research 13 
needs to be carried out specifically in the context of corneal transplantation. 14 
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FIGURE LEGENDS 1 
FIGURE 1. Long term corneal allograft survival. Kaplan-Meier plots show the survival of 2 
penetrating, lamellar and limbal corneal grafts within the Australian Corneal Graft 3 
Registry database. Modified with permission from The Australian Corneal Graft Registry 4 
Report 2004, eds KA Williams, NB Hornsby, CM Bartlett, HK Holland, A Esterman, DJ 5 
Coster. Adelaide: Snap Printing 2004, pp1-192. 6 
FIGURE 2. The influence of indication for transplantation on corneal allograft survival. 7 
Kaplan-Meier plots show the survival of penetrating corneal grafts within the Australian 8 
Corneal Graft Registry database. Modified with permission from The Australian Corneal 9 
Graft Registry Report 2004, eds KA Williams, NB Hornsby, CM Bartlett, HK Holland, A 10 
Esterman, DJ Coster. Adelaide: Snap Printing 2004, pp1-192. 11 
FIGURE 3. The influence of ipsilateral ocular inflammation prior to, or at the time of 12 
corneal transplantation, on corneal allograft survival. Kaplan-Meier plots show the 13 
survival of penetrating corneal grafts within the Australian Corneal Graft Registry 14 
database. Modified with permission from The Australian Corneal Graft Registry Report 15 
2004, eds KA Williams, NB Hornsby, CM Bartlett, HK Holland, A Esterman, DJ Coster. 16 
Adelaide: Snap Printing 2004, pp1-192. 17 
FIGURE 4. The influence of corneal neovascularization at the time of transplantation on 18 
corneal allograft survival. Kaplan-Meier plots show the survival of penetrating corneal 19 
grafts within the Australian Corneal Graft Registry database. Modified with permission 20 
from The Australian Corneal Graft Registry Report 2004, eds KA Williams, NB Hornsby, 21 
CM Bartlett, HK Holland, A Esterman, DJ Coster. Adelaide: Snap Printing 2004, pp1-22 
192. 23 
FIGURE 5. The influence of a history of raised intraocular pressure on corneal allograft 24 
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survival. Kaplan-Meier plots show the survival of penetrating corneal grafts within the 1 
Australian Corneal Graft Registry database. Modified with permission from The 2 
Australian Corneal Graft Registry Report 2004, eds KA Williams, NB Hornsby, CM 3 
Bartlett, HK Holland, A Esterman, DJ Coster. Adelaide: Snap Printing 2004, pp1-192. 4 
FIGURE 6. The influence of repeated keratoplasty in the ipsilateral eye on corneal 5 
allograft survival. Kaplan-Meier plots show the survival of penetrating corneal grafts 6 
within the Australian Corneal Graft Registry database. Modified with permission from 7 
The Australian Corneal Graft Registry Report 2004, eds KA Williams, NB Hornsby, CM 8 
Bartlett, HK Holland, A Esterman, DJ Coster. Adelaide: Snap Printing 2004, pp1-192. 9 
FIGURE 7. The mechanisms involved in corneal graft rejection. 10 
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